Anna P. Durbin, M.D. is a Professor of International Health in the Bloomberg School of Public Health with a joint appointment in the School of Medicine. She is trained in Internal Medicine and Infectious Diseases. Dr. Durbin came to the Center for Immunization Research in 1999 as a Principal Investigator conducting clinical trials for live attenuated flavivirus vaccines. She has expertise in the evaluation of a variety of vaccines, including Dengue, West Nile and Malaria. Dr. Durbin’s early work evaluating monovalent Dengue vaccines for Dengue types 1, 2, 3, & 4 and subsequent evaluations of several bivalent, trivalent and tetravalent Dengue vaccine formulations has produced live attenuated Dengue vaccine candidates (DENV TV003 and DENV TV005) capable of producing immunity to all four Dengue types. An important research interest of hers is studying the immunopathogenesis of dengue infection and disease. Dr. Durbin collaborated with the National Institutes of Health to develop a controlled dengue human challenge model for the early evaluation of vaccine efficacy as well as the study of dengue protective and infection enhancing immunity. She has served on national and international advisory boards and committees related to dengue and malaria vaccine safety as well as the JHSPH Institutional Review Board. Dr. Durbin received the NIH Merit Award for outstanding basic and translational research in developing vaccines for the prevention of respiratory virus and flavivirus diseases, NIH Director’s Award and the Vaccine Industry Excellence Award for Best Academic Research Team.
PublicationsDengue vascular leak syndrome: insights into potentially new treatment modalities Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by NIH Monovalent Dengue Virus Vaccines What is the Prospect of a Safe and Effective Dengue Vaccine for Travelers? Cutting Edge: Transcriptional Profiling Reveals Multifunctional and Cytotoxic Antiviral Responses of Zika Virus-Specific CD8+ T Cells Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization